Elo Mutual Pension Insurance Co Has $5 Million Holdings in Edwards Lifesciences Co. (NYSE:EW)

Elo Mutual Pension Insurance Co cut its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 2.2% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 54,077 shares of the medical research company’s stock after selling 1,224 shares during the quarter. Elo Mutual Pension Insurance Co’s holdings in Edwards Lifesciences were worth $4,995,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Price T Rowe Associates Inc. MD lifted its holdings in shares of Edwards Lifesciences by 57.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,516,260 shares of the medical research company’s stock valued at $622,695,000 after buying an additional 2,390,137 shares during the last quarter. CIBC Private Wealth Group LLC lifted its holdings in shares of Edwards Lifesciences by 197.0% during the 4th quarter. CIBC Private Wealth Group LLC now owns 3,446,758 shares of the medical research company’s stock valued at $262,815,000 after buying an additional 2,286,119 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Edwards Lifesciences by 9.5% during the 1st quarter. Bank of New York Mellon Corp now owns 18,973,304 shares of the medical research company’s stock valued at $1,813,089,000 after buying an additional 1,644,869 shares during the last quarter. Sands Capital Management LLC lifted its holdings in shares of Edwards Lifesciences by 34.6% during the 4th quarter. Sands Capital Management LLC now owns 6,103,702 shares of the medical research company’s stock valued at $465,407,000 after buying an additional 1,567,526 shares during the last quarter. Finally, CCLA Investment Management lifted its holdings in shares of Edwards Lifesciences by 100,739.7% during the 1st quarter. CCLA Investment Management now owns 1,406,714 shares of the medical research company’s stock valued at $134,092,000 after buying an additional 1,405,319 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Stock Performance

EW opened at $67.53 on Thursday. The stock has a market cap of $40.69 billion, a PE ratio of 29.11, a P/E/G ratio of 2.85 and a beta of 1.13. The company has a current ratio of 3.71, a quick ratio of 2.87 and a debt-to-equity ratio of 0.08. Edwards Lifesciences Co. has a 1 year low of $58.93 and a 1 year high of $96.12. The stock’s 50 day simple moving average is $70.89 and its 200-day simple moving average is $83.11.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Wednesday, July 24th. The medical research company reported $0.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.69 by $0.01. The business had revenue of $1.63 billion for the quarter, compared to analysts’ expectations of $1.65 billion. Edwards Lifesciences had a return on equity of 22.35% and a net margin of 24.55%. Edwards Lifesciences’s quarterly revenue was up 6.7% on a year-over-year basis. During the same period in the previous year, the business posted $0.66 earnings per share. Sell-side analysts forecast that Edwards Lifesciences Co. will post 2.7 EPS for the current year.

Insider Activity

In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 14th. The stock was sold at an average price of $66.08, for a total transaction of $330,400.00. Following the sale, the vice president now directly owns 46,936 shares in the company, valued at $3,101,530.88. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction on Wednesday, August 14th. The stock was sold at an average price of $66.08, for a total transaction of $330,400.00. Following the completion of the transaction, the vice president now directly owns 46,936 shares in the company, valued at $3,101,530.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Daveen Chopra sold 1,250 shares of the stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total value of $87,437.50. Following the transaction, the vice president now owns 29,333 shares of the company’s stock, valued at $2,051,843.35. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 16,250 shares of company stock worth $1,218,138. Company insiders own 1.29% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently issued reports on EW. Baird R W lowered Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 25th. Jefferies Financial Group lowered Edwards Lifesciences from a “buy” rating to a “hold” rating and reduced their target price for the stock from $85.00 to $70.00 in a report on Wednesday. Daiwa America upgraded Edwards Lifesciences to a “strong-buy” rating in a report on Wednesday, July 31st. Canaccord Genuity Group reduced their target price on Edwards Lifesciences from $85.00 to $77.00 and set a “hold” rating for the company in a report on Thursday, July 25th. Finally, Bank of America lowered Edwards Lifesciences from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $105.00 to $75.00 in a report on Thursday, July 25th. Sixteen research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $79.82.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.